All types of locally advanced and metastatic malignancy
Male/female participants
Age\>18 y.o.
Signed informed consent for participation in the study
No restriction on Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) Performance Status
Subject should not have received a prior systemic anti-viral treatment for Covid19 disease.
You may not be if
Patients with known hypersensitivity to hydroxychloroquine or chloroquine, azithromycin, erythromycin, or any other macrolide, ketolide or any of the excipients of the hydroxychloroquine and/or azithromycin-based specialty used.
Severe hepatic impairment and patients with severe cholestasis.
Patients with renal insufficiency with creatinine clearance \< 40 mL/min.
Combinations of drugs contraindicated in accordance with the approvals of the specialties used.
Patients currently treated with Tamoxifen
Patients already treated by hydroxychloroquine or azithromycin for Covid19 disease or currently treated with other antiviral drugs against coronavirus.
Patients with known contra-indication to treatment with the study drug, including retinopathy, G6PD deficiency, QT prolongation and severe hepato-cellular insufficiency.
Patients post allogeneic hematopoietic stem cell transplantation are eligible to the Part B treatments but the potential toxic effects of hydroxychloroquin and azithromycin on hematopoietic stem cells should be taken into consideration by prescribers.
Pregnant or breastfeeding women. Women of childbearing potential (WOCBP, as defined in appendix 2) should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
